Septerna (NASDAQ:SEPN) Upgraded to Hold at Wall Street Zen

Septerna (NASDAQ:SEPN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other equities analysts have also recently issued reports on SEPN. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of Septerna in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Septerna in a research note on Thursday, August 21st. Finally, Wells Fargo & Company boosted their price objective on Septerna from $11.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 16th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.75.

Septerna Price Performance

NASDAQ SEPN opened at $14.43 on Friday. Septerna has a 12 month low of $4.17 and a 12 month high of $28.99. The company has a market capitalization of $643.29 million and a P/E ratio of -1.43. The company’s 50 day simple moving average is $12.11 and its 200 day simple moving average is $9.10.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.51). The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%. On average, analysts anticipate that Septerna will post -7.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SEPN. Tower Research Capital LLC TRC acquired a new position in shares of Septerna in the fourth quarter worth about $25,000. The Manufacturers Life Insurance Company acquired a new position in shares of Septerna in the fourth quarter worth about $506,000. Northern Trust Corp acquired a new position in shares of Septerna in the fourth quarter worth about $3,384,000. Jane Street Group LLC acquired a new position in shares of Septerna in the fourth quarter worth about $600,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Septerna during the fourth quarter worth approximately $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.